Incorporating Genomic Testing For Prostate Cancer into Your Practice (2021)

CME Available: https://auau.auanet.org/node/31455

ACKNOWLEDGEMENTS

Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.

At the conclusion of the activity, participants will be able to:

1. Describe the seminal validation studies for prostate cancer genomic testing.

2. List the different prognostic endpoints provided by various genomic tests.

3. Identify appropriate genomic testing based on a patient's unique clinical characteristics.

4. Review the AUA and NCCN guidelines for genomic testing for prostate cancer.